The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans

Gottesman, 1993, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem., 62, 385, 10.1146/annurev.bi.62.070193.002125 Higgins, 1992, Is the multidrug transporter a flippase?, Trends Biochem. Sci., 17, 18, 10.1016/0968-0004(92)90419-A Ambudkar, 1999, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu. Rev. Pharmacol. Toxicol., 39, 361, 10.1146/annurev.pharmtox.39.1.361 Litman, 2001, From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance, Cell Mol. Life Sci., 58, 931, 10.1007/PL00000912 Watkins, 1997, The barrier function of CYP3A4 and P-glycoprotein in the small bowel, Adv. Drug Deliv. Rev., 27, 161, 10.1016/S0169-409X(97)00041-0 Benet, 2001, The drug efflux-metabolism alliance: biochemical aspects, Adv. Drug Deliv. Rev., 50, S3, 10.1016/S0169-409X(01)00178-8 Ayrton, 2001, Role of transport proteins in drug absorption, distribution and excretion, Xenobiotica, 31, 469, 10.1080/00498250110060969 Greiner, 1999, The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin, J. Clin. Invest., 104, 147, 10.1172/JCI6663 Fromm, 1999, Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine, Circulation, 99, 552, 10.1161/01.CIR.99.4.552 Westphal, 2000, Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction, Clin. Pharmacol. Ther., 68, 345, 10.1067/mcp.2000.109797 Thiebaut, 1987, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues, Proc. Natl. Acad. Sci. U.S.A., 84, 7735, 10.1073/pnas.84.21.7735 Cordon-Cardo, 1989, Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites, Proc. Natl. Acad. Sci. U.S.A., 86, 695, 10.1073/pnas.86.2.695 Rao, 1999, Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier, Proc. Natl. Acad. Sci. U.S.A., 96, 3900, 10.1073/pnas.96.7.3900 MacFarland, 1994, Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta, Histochem. J., 26, 417, 10.1007/BF00160054 Klimecki, 1994, P-glycoprotein expression and function in circulating blood cells from normal volunteers, Blood, 83, 2451, 10.1182/blood.V83.9.2451.2451 Wacher, 1995, Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy, Mol. Carcinog., 13, 129, 10.1002/mc.2940130302 Kim, 1999, Interrelationship between substrates and inhibitors of human CYP3A and P-glykoprotein, Pharm. Res., 16, 408, 10.1023/A:1018877803319 Cvetkovic, 1999, OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine, Drug Metab. Dispos., 27, 866 Kullak-Ublick, 2001, Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver, Gastroenterology, 120, 525, 10.1053/gast.2001.21176 Mickley, 1998, Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors, Blood, 91, 1749, 10.1182/blood.V91.5.1749 Hoffmeyer, 2000, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc. Natl. Acad. Sci. U.S.A., 97, 3473, 10.1073/pnas.050585397 Cascorbi, 2001, Frequency of single nucleotide polymorphisms (SNPs) in the P-glycoprotein drug transporter MDR1 gene in Caucasians, Clin. Pharmacol. Ther., 69, 169, 10.1067/mcp.2001.114164 Kim, 2001, Identification of functionally variant MDR1 alleles among European Americans and African Americans, Clin. Pharmacol. Ther., 70, 189, 10.1067/mcp.2001.117412 Schaeffeler, 2001, Application of DHPLC to detect known and novel mutations in the MDR1 gene in different ethnicities, Pharmacol. Toxicol. (Abstract), 89, 105 Tanabe, 2001, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene, J. Pharmacol. Exp. Ther., 297, 1137 Nakamura, 2002, Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects, Clin. Pharmacol. Ther., 71, 297, 10.1067/mcp.2002.122055 Hitzl, 2001, The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells, Pharmacogenetics, 11, 1, 10.1097/00008571-200106000-00003 Fellay, 2002, for the Swiss HIV Cohort Study, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenentics study, Lancet, 359, 30, 10.1016/S0140-6736(02)07276-8 Sakaeda, 2001, MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects, Pharm. Res., 18, 1400, 10.1023/A:1012244520615 Schinkel, 1996, P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs, J. Clin. Invest., 97, 2517, 10.1172/JCI118699 Kerb, 2001, The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels, Pharmacogenomics, 1, 204, 10.1038/sj.tpj.6500025 Pauli-Magnus, 2002, No effect of MDR1 C3435T polymorphism on disposition and CNS effects of loperamide, Clin. Pharmacol. Ther. (Abstract), 71, P72 Gießmann, 2001, The disposition of talinolol is influenced by the MDR1 genotype in man, Naunyn Schmiedebergs Arch. Pharmacol. (Abstract), 363, R120 Drescher, 2002, MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine, Br. J. Clin. Pharmacol., 53, 526, 10.1046/j.1365-2125.2002.01591.x Kim, 1998, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J. Clin. Invest., 101, 289, 10.1172/JCI1269 Alsenz, 1998, Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Coco-2 cell monolayers, Pharm. Res., 15, 423, 10.1023/A:1011924314899 Lee, 1998, HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter, Biochemistry, 37, 3594, 10.1021/bi972709x Lee, 2000, Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter, FASEB J., 14, 516, 10.1096/fasebj.14.3.516 Choo, 2000, Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes, Drug Metab. Dispos., 28, 655 Huang, 2001, Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors, Drug Metab. Dispos., 29, 754 Schuetz, 1996, P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans, Proc. Natl. Acad. Sci. U.S.A., 93, 4001, 10.1073/pnas.93.9.4001 Lan, 2000, Mdr1 limits CYP3A metabolism in vivo, Mol. Pharmacol., 58, 863, 10.1124/mol.58.4.863 Lown, 1997, Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine, Clin. Pharmacol. Ther., 62, 248, 10.1016/S0009-9236(97)90027-8 von Ahsen, 2001, No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients, Clin. Chem., 47, 1048, 10.1093/clinchem/47.6.1048 Wandel, 2001, ‘Inactive’ ingredients may alter bioavailability of drugs through effects on P-glycoprotein (PGP) and CYP3A, Clin. Pharmacol. Ther. (Abstract), 69, P71 Stanulla, 2001, An association between the MDR1 C3435T polymorphism and CNS relapse in childhood ALL, Eur. J. Clin. Pharmacol. (Abstract), 57, A28 Furuno, 2001, MDR1 polymorphism and Parkinson’s disease, Drug Metab. Rev. (Abstract), 33, 129 Hermiston, 1995, Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin, Science, 270, 1203, 10.1126/science.270.5239.1203 Dianda, 1997, T cell receptor–alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment, Am. J. Pathol., 150, 91 Panwala, 1998, A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis, J. Immunol., 161, 5733, 10.4049/jimmunol.161.10.5733 Schaeffeler, 2001, Frequency of C3435T polymorphism of MDR1 gene in African people, Lancet, 358, 383, 10.1016/S0140-6736(01)05579-9 Ameyaw, 2001, MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity, Pharmacogenetics, 11, 217, 10.1097/00008571-200104000-00005 Min, 2000, Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers, Clin. Pharmacol. Ther., 68, 478, 10.1067/mcp.2000.111255 Mancinelli, 2001, The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups, Clin. Pharmacol. Ther., 69, 24, 10.1067/mcp.2001.113183 Ito, 2001, Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects, Pharmacogenetics, 11, 175, 10.1097/00008571-200103000-00008 Dürr, 2000, St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4, Clin. Pharmacol. Ther., 68, 598, 10.1067/mcp.2000.112240 Cordon-Cardo, 1990, Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues, J. Histochem. Cytochem., 38, 1277, 10.1177/38.9.1974900 Lankas, 1998, Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice, Reprod. Toxicol., 12, 457, 10.1016/S0890-6238(98)00027-6 Jette, 1995, Interaction of drugs with P-glycoprotein in brain capillaries, Biochem. Pharmacol., 50, 1701, 10.1016/0006-2952(95)02073-X Wils, 1994, Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers, Biochem. Pharmacol., 48, 1528, 10.1016/0006-2952(94)90580-0 Bart, 2000, The blood–brain barrier and oncology: new insights into function and modulation, Cancer Treat. Rev., 26, 449, 10.1053/ctrv.2000.0194 Sugiyama, 1998, Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein, Cancer Chemother. Pharmacol., 42, S44, 10.1007/s002800051078 Relling, 1996, Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?, Ther. Drug Monit., 18, 350, 10.1097/00007691-199608000-00006 Sparreboom, 1997, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine, Proc. Natl. Acad. Sci. U.S.A., 94, 2031, 10.1073/pnas.94.5.2031 Hoki, 1997, Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines, Cancer Chemother. Pharmacol., 40, 433, 10.1007/s002800050682 Schinkel, 1994, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs, Cell, 77, 491, 10.1016/0092-8674(94)90212-7 Pauli-Magnus, 2001, P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin, Naunyn Schmiedebergs Arch. Pharmacol., 363, 337, 10.1007/s002100000354 Schinkel, 1995, Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A, J. Clin. Invest., 96, 1698, 10.1172/JCI118214 Polli, 1999, Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor, Pharm. Res., 16, 1206, 10.1023/A:1018941328702 Saeki, 1993, Human P-glycoprotein transports cyclosporin A and FK506, J. Biol. Chem., 268, 6077, 10.1016/S0021-9258(18)53221-X Schuetz, 1998, Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene, Arch. Biochem. Biophys., 350, 340, 10.1006/abbi.1997.0537 Ito, 1997, Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1, J. Pharmacol. Exp. Ther., 282, 955 de Lange, 2000, In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin, Eur. J. Pharm. Sci., 12, 85, 10.1016/S0928-0987(00)00149-4 Wu, 2000, Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter, Pharm. Res., 17, 209, 10.1023/A:1007525616017 Saeki, 1993, P-glycoprotein-mediated transcellular transport of MDR-reversing agents, FEBS Lett., 324, 99, 10.1016/0014-5793(93)81540-G Wandel, 2000, Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro, Drug Metab. Dispos., 28, 895 Pauli-Magnus, 2000, Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein, J. Pharmacol. Exp. Ther., 293, 376 Matsuzaki, 1999, Contribution of P-glycoprotein to bunitrolol efflux across blood–brain barrier, Biopharm. Drug Dispos., 20, 85, 10.1002/(SICI)1099-081X(199903)20:2<85::AID-BDD159>3.0.CO;2-3 Karlsson, 1993, Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein, Br. J. Pharmacol., 110, 1009, 10.1111/j.1476-5381.1993.tb13914.x Wetterich, 1996, Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo, Pharm. Res., 13, 514, 10.1023/A:1016029601311 Collett, 1999, Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2, J. Pharmacol. Exp. Ther., 288, 171 Desrayaud, 1997, Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine, Life Sci., 61, 153, 10.1016/S0024-3205(97)00370-6 Soldner, 2000, Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers, Br. J. Pharmacol., 129, 1235, 10.1038/sj.bjp.0703150 Declèves, 2000, A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein, Hum. Mutat., 15, 486, 10.1002/(SICI)1098-1004(200005)15:5<486::AID-HUMU26>3.0.CO;2-P Chen, 1990, Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins, J. Biol. Chem., 265, 506, 10.1016/S0021-9258(19)40260-3 Yoon, 2002, Genetic and environmental factors influencing on the disposition of digoxin: a population pharmacokinetic approach, Clin. Pharmacol. Ther. (Abstract), 71, P73 Shon, 2002, The PK and PD of fexofenadine in relation to MDR1 genetic polymorphism in Korean healthy subjects, Clin. Pharmacol. Ther. (Abstract), 71, P71